



Notice of Changes to 340B Prices

February 5th, 2025

Sumitomo Pharma America(SMPA) has submitted routine updated Medicaid Drug Rebate Program data to the Centers for Medicare and Medicaid Services (CMS) for Q1 2022 to Q4 2022 for certain covered outpatient drugs. Based on this updated data, SMPA has determined that a lower 340B ceiling price applied to certain quarters for the following NDCs:

NDC11	PROD_DESC	Price Inc/Dec	Comment
73336007530	Gemtesa 75mg 30 tablets	Decrease	Repayment Offered
73336007590	Gemtesa 75mg 90 tablets	Decrease	Repayment Offered
63402001030	Kynmobi 10mg 30ct Carton	Decrease	Repayment Offered
63402030230	Latuda 20mg 30 Tablets	Decrease	Repayment Offered
63402030430	Latuda 40mg 30 Tablets	Decrease	Repayment Offered
63402030630	Latuda 60mg 30 Tablets	Decrease	Repayment Offered
63402030830	Latuda 80mg 30 Tablets	Decrease	Repayment Offered
63402030101	Lonhala Magnair 25mcg/1mL 60 Vials Refil	Decrease	Repayment Offered
63402020100	Lonhala Magnair 25mcg/1mL 60 Vials Starter	Decrease	Repayment Offered
63402002530	Kynmobi 25mg 30ct Carton	Increase	No Repayment Sought After
63402003030	Kynmobi 30mg 30ct Carton	Increase	No Repayment Sought After
63402031230	Latuda 120mg 30 Tablets	Increase	No Repayment Sought After
72974041501	Myfembree 40mg 28 tablets	Increase	No Repayment Sought After
72974012001	Orgovyx 120mg 30 Tablets	Increase	No Repayment Sought After

Where the updated data resulted in a higher 340B ceiling price, SMPA will not seek repayments from Covered Entities.

SMPA is offering refunds to impacted Covered Entities that purchased the above NDCs at a higher 340B ceiling price during the applicable quarters. SMPA will directly contact Covered Entities who may be eligible for a refund of \$50.00 or more. SMPA will not directly contact or issue checks to Covered Entities who may be eligible for amounts less than \$50.00 resulting from this restatement. For Covered Entities who believe they may be entitled to a refund amount less than \$50.00, they may contact SMPA at membership@SMPA.com. Any Covered Entity may also contact membership@SMPA.com with any questions about this Notice.

SMPA is committed to complying with all 340B Drug Discount Program requirements. We have requested that Health Resource and Services Administration (HRSa) post this Notice on the HRSa website to ensure transparency to Covered Entities regarding SMPA's resubmitted data and refund process.